source
- FDA rejects Capricor's Duchenne cell therapy again, citing major trial flawsCapricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy was denied by the FDA for a second time. The agency highlighted significant issues with the trial design and data, le…
- It’s Over-ton; Thoughts on Isomorphic’s latest haul; and moreWelcome back to another edition of Endpoints Weekly! All the tech outages this week can’t stop us from bringing you the latest in biopharma news. The biggest news this week came from Washington, wh…Endpoints · 1h ago↗ source